Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

View:
Post by prophetoffactz on Feb 24, 2023 7:23pm

Protalix

Protalix traded 3.82 million shares and now has a C$124 million market cap. There is more certainty as to its future today. It could theoretically be in a much better position to acquire and absorb BTI now for C$40 million. That would only mean 32% more shares for it. It could pick up the brain for Fabry. It has a Gaucher's enzyme. It has a relationship with Chiesi.
Comment by Boomskid on Feb 24, 2023 9:35pm
Yes, Protalix likely has a continuing relationship with Chiesi, as I post back in 2020. Therefore, Protalix likely has a relationship with Bioasis.  Unfortunately, Bioasis has already been paid by Chiesi for its LSDs. Future developmental, regulatory and commercial milestone payments are set at an average of $34.5 million per LSD. There is also a royalty that can't come into play for ...more  
Comment by ROSIE2023 on Feb 24, 2023 11:01pm
What and why can't the royalty come into play for m at years  thanks 
Comment by prophetoffactz on Feb 25, 2023 9:41am
"Unfortunately, Bioasis has already been paid by Chiesi for its LSDs. Future developmental, regulatory and commercial milestone payments are set at an average of $34.5 million per LSD. There is also a royalty that can't come into play for many years." If the Chiesi/xB3 deal is worth C$500 million in upfront, potential milestones, and potential royalty payments in the future under ...more  
Comment by G1945V on Feb 25, 2023 9:56am
"The outcome could be bankruptcy to significant surprise." Well not directly to bankruptcy. BTI would apply to the Court for protection under the "Companies' Creditors Arrangement Act" (CCAA). Stranger things have happened to companies in that type of situation. "Also, the J&J multi-product option appears to have progressed." Progressed into what exactly? ...more  
Comment by prophetoffactz on Feb 25, 2023 11:04am
""Also, the J&J multi-product option appears to have progressed." Progressed into what exactly?" There was no replay of the AGM that I'm aware of but I believe Rathjen said the J&J deal was extended, expanded, and a small milestone payment to BTI was made.
Comment by G1945V on Feb 25, 2023 11:33am
"Rathjen said the J&J deal was extended, expanded, and a small milestone payment to BTI was made." Don't know the date of what Rathjen said, allegedly. So does it mean that the J&J deal is still alive? G1945V
Comment by prophetoffactz on Feb 25, 2023 12:23pm
"Rathjen said the J&J deal was extended, expanded, and a small milestone payment to BTI was made." Don't know the date of what Rathjen said, allegedly. So does it mean that the J&J deal is still alive? ----- I believe that's what she said at the AGM which was held Feb. 3. The J&J option was set to expire Jan. 31, 2023. 
Comment by ROSIE2023 on Feb 26, 2023 9:31pm
What relationship does BTI have with protalix